174 related articles for article (PubMed ID: 34545504)
1. Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
Dettwyler SA; Koeppe ES; Jacobs MF; Stoffel EM
Fam Cancer; 2022 Jul; 21(3):375-385. PubMed ID: 34545504
[TBL] [Abstract][Full Text] [Related]
2. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
[TBL] [Abstract][Full Text] [Related]
3. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
Garcia-Pelaez J; Barbosa-Matos R; Lobo S; Dias A; Garrido L; Castedo S; Sousa S; Pinheiro H; Sousa L; Monteiro R; Maqueda JJ; Fernandes S; Carneiro F; Pinto N; Lemos C; Pinto C; Teixeira MR; Aretz S; Bajalica-Lagercrantz S; Balmaña J; Blatnik A; Benusiglio PR; Blanluet M; Bours V; Brems H; Brunet J; Calistri D; Capellá G; Carrera S; Colas C; Dahan K; de Putter R; Desseignés C; Domínguez-Garrido E; Egas C; Evans DG; Feret D; Fewings E; Fitzgerald RC; Coulet F; Garcia-Barcina M; Genuardi M; Golmard L; Hackmann K; Hanson H; Holinski-Feder E; Hüneburg R; Krajc M; Lagerstedt-Robinson K; Lázaro C; Ligtenberg MJL; Martínez-Bouzas C; Merino S; Michils G; Novaković S; Patiño-García A; Ranzani GN; Schröck E; Silva I; Silveira C; Soto JL; Spier I; Steinke-Lange V; Tedaldi G; Tejada MI; Woodward ER; Tischkowitz M; Hoogerbrugge N; Oliveira C
Lancet Oncol; 2023 Jan; 24(1):91-106. PubMed ID: 36436516
[TBL] [Abstract][Full Text] [Related]
4. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
[TBL] [Abstract][Full Text] [Related]
5. Results from London Regional Clinical Genetics services over a 5-year period on germline
Garrett A; Talukdar S; Izatt L; Brady AF; Whyte S; Josephs KS; Shanmugasundaram M; Guillemot LS; Vakili D; Ey S; Ahmed M
J Med Genet; 2022 Jun; 59(6):554-558. PubMed ID: 34266904
[TBL] [Abstract][Full Text] [Related]
6. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
[TBL] [Abstract][Full Text] [Related]
7. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
[TBL] [Abstract][Full Text] [Related]
8. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
Nizic-Kos T; Krajc M; Blatnik A; Stegel V; Skerl P; Novakovic S; Gazic B; Besic N
Ann Surg Oncol; 2021 May; 28(5):2561-2570. PubMed ID: 33030641
[TBL] [Abstract][Full Text] [Related]
9. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
10. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
Lee J; Ham JY; Park HY; Jung JH; Kim WW; Kang B; Chae YS; Lee SJ; Lee IH; Lee NY
Sci Rep; 2022 Feb; 12(1):1842. PubMed ID: 35115620
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of retesting BRCA negative patients using multigene panels.
Yadav S; Reeves A; Campian S; Paine A; Zakalik D
Fam Cancer; 2017 Jul; 16(3):319-328. PubMed ID: 27878467
[TBL] [Abstract][Full Text] [Related]
13. PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.
Siraj AK; Bu R; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Victoria IG; Al-Badawi IA; Tulbah A; Al-Dayel F; Ajarim D; Al-Kuraya KS
Sci Rep; 2023 May; 13(1):7666. PubMed ID: 37169825
[TBL] [Abstract][Full Text] [Related]
14. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
15. Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.
Al Saati A; Vande Perre P; Plenecassagnes J; Gilhodes J; Monselet N; Cabarrou B; Lignon N; Filleron T; Telly D; Perello-Lestrade E; Feillel V; Staub A; Martinez M; Chipoulet E; Collet G; Thomas F; Gladieff L; Toulas C
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762649
[TBL] [Abstract][Full Text] [Related]
16. Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country.
Krivokuca A; Mihajlovic M; Susnjar S; Spasojevic IB; Minic I; Popovic L; Brankovic-Magic M
Curr Probl Cancer; 2022 Feb; 46(1):100767. PubMed ID: 34284872
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore.
Zhang Z; Ishak NDB; Que FVF; Chua ZY; Chan SH; Chiang J; Yie JNY
Hered Cancer Clin Pract; 2023 Apr; 21(1):5. PubMed ID: 37046302
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in
Stegel V; Blatnik A; Škof E; Dragoš VŠ; Krajc M; Gregorič B; Škerl P; Strojnik K; Klančar G; Banjac M; Žgajnar J; Ravnik M; Novaković S
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326583
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of mutations in a diverse cohort of 3162 women tested via the same multigene cancer panel in a managed care health plan.
Alvarado M; Tiller GE; Chung J; Haque R
J Community Genet; 2020 Jul; 11(3):359-366. PubMed ID: 32096056
[TBL] [Abstract][Full Text] [Related]
20. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
Macklin-Mantia SK; Clift KE; Maimone S; Hodge DO; Riegert-Johnson D; Hines SL
J Genet Couns; 2023 Jun; 32(3):598-606. PubMed ID: 36478495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
